Loading…
5PSQ-020 Analysis of the effectiveness of secukinumab and ixekizumab in the treatment of moderate–severe psoriasis
Background and importanceThere are currently two drugs with the same mechanism of action, inhibitors of interleukin 17 (anti-IL-17), for the treatment of moderate–severe psoriasis.Aim and objectivesTo evaluate the efficacy of secukinumab and ixekizumab in terms of psoriasis area severity index (PASI...
Saved in:
Published in: | European journal of hospital pharmacy. Science and practice 2020-03, Vol.27 (Suppl 1), p.A159-A159 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | A159 |
container_issue | Suppl 1 |
container_start_page | A159 |
container_title | European journal of hospital pharmacy. Science and practice |
container_volume | 27 |
creator | Sanchez Matamoros Piazza, MDV Varas Perez, A Puivecino Moreno, C Cuadros Martinez, C |
description | Background and importanceThere are currently two drugs with the same mechanism of action, inhibitors of interleukin 17 (anti-IL-17), for the treatment of moderate–severe psoriasis.Aim and objectivesTo evaluate the efficacy of secukinumab and ixekizumab in terms of psoriasis area severity index (PASI) and dermatology life quality index (DLQI) in the treatment of moderate–severe psoriasisMaterial and methodsA retrospective observational study was conducted in patients treated with secukinumab and ixekizumab from February 2016 to October 2019. The variables collected were sex, diagnosis and previous biological treatment. The variation in PASI and DLQI were studied as the main efficacy variables. Data were obtained from the record of dispensation of outpatients and the electronic medical history.ResultsEighty-four patients were included, 44% were men. In 50% of cases the anti-IL-17 drug was used as the firstline biological treatment, in 27% of cases as the secondline, in 6% as the thirdline and in 7% as the fourthline or successive treatment. The baseline average PASI was 6.87 (SD=3.5) and the average DLQI was 7.07 (SD=3.73). Twenty-one patients could not be evaluated due to lack of data recorded after the start of the anti-IL-17 drug. The percentage of patients with a reduced PASI was 9.52%, 19.05% and 44.44% for PASI 75/90/100, respectively: 63.16% obtained a DLQI after the start of treatment of 0–1.Conclusion and relevanceSecukinumab and ixekizumab demonstrated effectiveness, representing a good therapeutic option for moderate to severe plaque psoriasis, including in both naive and patients refractory to other biological treatments. It is necessary to continue monitoring these patients to study the long term results.References and/or acknowledgementsNo conflict of interest. |
doi_str_mv | 10.1136/ejhpharm-2020-eahpconf.337 |
format | article |
fullrecord | <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_2382936617</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2382936617</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1267-cdb21f2c95c99db3e5c1a510e70f54be449a34bf7f00abc5332d8a68ca14dcff3</originalsourceid><addsrcrecordid>eNo9kMlOwzAURSMEElXpP0SwTvGYxMuqYpIqAQLWlu08K26bATutgFU3fAF_2C8hbSmrN-je93RPFF1iNMaYptcwL9tS-SohiKAEVNmaprZjSrOTaEAQyxIhUnb63_P0PBqF4DTilOaCUTGI1vzp5Tnp_dvN96RWy8_gQtzYuCshBmvBdG4NNYT9MoBZLVy9qpSOVV3E7gMW7ms_unpv6TyoroK628mrpgCvOthufgKswUPchsY71b-4iM6sWgYY_dVh9HZ78zq9T2aPdw_TySzRmKRZYgpNsCVGcCNEoSlwgxXHCDJkOdPAmFCUaZtZhJQ2fSxS5CrNjcKsMNbSYXR1uNv65n0FoZPzZuX7nEESmhNB0xRnvYofVLqay9a7SvlPiZHcUZZHynJHWR4py54y_QUxdXm5</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2382936617</pqid></control><display><type>article</type><title>5PSQ-020 Analysis of the effectiveness of secukinumab and ixekizumab in the treatment of moderate–severe psoriasis</title><source>Open Access: PubMed Central</source><creator>Sanchez Matamoros Piazza, MDV ; Varas Perez, A ; Puivecino Moreno, C ; Cuadros Martinez, C</creator><creatorcontrib>Sanchez Matamoros Piazza, MDV ; Varas Perez, A ; Puivecino Moreno, C ; Cuadros Martinez, C</creatorcontrib><description>Background and importanceThere are currently two drugs with the same mechanism of action, inhibitors of interleukin 17 (anti-IL-17), for the treatment of moderate–severe psoriasis.Aim and objectivesTo evaluate the efficacy of secukinumab and ixekizumab in terms of psoriasis area severity index (PASI) and dermatology life quality index (DLQI) in the treatment of moderate–severe psoriasisMaterial and methodsA retrospective observational study was conducted in patients treated with secukinumab and ixekizumab from February 2016 to October 2019. The variables collected were sex, diagnosis and previous biological treatment. The variation in PASI and DLQI were studied as the main efficacy variables. Data were obtained from the record of dispensation of outpatients and the electronic medical history.ResultsEighty-four patients were included, 44% were men. In 50% of cases the anti-IL-17 drug was used as the firstline biological treatment, in 27% of cases as the secondline, in 6% as the thirdline and in 7% as the fourthline or successive treatment. The baseline average PASI was 6.87 (SD=3.5) and the average DLQI was 7.07 (SD=3.73). Twenty-one patients could not be evaluated due to lack of data recorded after the start of the anti-IL-17 drug. The percentage of patients with a reduced PASI was 9.52%, 19.05% and 44.44% for PASI 75/90/100, respectively: 63.16% obtained a DLQI after the start of treatment of 0–1.Conclusion and relevanceSecukinumab and ixekizumab demonstrated effectiveness, representing a good therapeutic option for moderate to severe plaque psoriasis, including in both naive and patients refractory to other biological treatments. It is necessary to continue monitoring these patients to study the long term results.References and/or acknowledgementsNo conflict of interest.</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2020-eahpconf.337</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Monoclonal antibodies ; Psoriasis</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2020-03, Vol.27 (Suppl 1), p.A159-A159</ispartof><rights>Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Sanchez Matamoros Piazza, MDV</creatorcontrib><creatorcontrib>Varas Perez, A</creatorcontrib><creatorcontrib>Puivecino Moreno, C</creatorcontrib><creatorcontrib>Cuadros Martinez, C</creatorcontrib><title>5PSQ-020 Analysis of the effectiveness of secukinumab and ixekizumab in the treatment of moderate–severe psoriasis</title><title>European journal of hospital pharmacy. Science and practice</title><description>Background and importanceThere are currently two drugs with the same mechanism of action, inhibitors of interleukin 17 (anti-IL-17), for the treatment of moderate–severe psoriasis.Aim and objectivesTo evaluate the efficacy of secukinumab and ixekizumab in terms of psoriasis area severity index (PASI) and dermatology life quality index (DLQI) in the treatment of moderate–severe psoriasisMaterial and methodsA retrospective observational study was conducted in patients treated with secukinumab and ixekizumab from February 2016 to October 2019. The variables collected were sex, diagnosis and previous biological treatment. The variation in PASI and DLQI were studied as the main efficacy variables. Data were obtained from the record of dispensation of outpatients and the electronic medical history.ResultsEighty-four patients were included, 44% were men. In 50% of cases the anti-IL-17 drug was used as the firstline biological treatment, in 27% of cases as the secondline, in 6% as the thirdline and in 7% as the fourthline or successive treatment. The baseline average PASI was 6.87 (SD=3.5) and the average DLQI was 7.07 (SD=3.73). Twenty-one patients could not be evaluated due to lack of data recorded after the start of the anti-IL-17 drug. The percentage of patients with a reduced PASI was 9.52%, 19.05% and 44.44% for PASI 75/90/100, respectively: 63.16% obtained a DLQI after the start of treatment of 0–1.Conclusion and relevanceSecukinumab and ixekizumab demonstrated effectiveness, representing a good therapeutic option for moderate to severe plaque psoriasis, including in both naive and patients refractory to other biological treatments. It is necessary to continue monitoring these patients to study the long term results.References and/or acknowledgementsNo conflict of interest.</description><subject>Monoclonal antibodies</subject><subject>Psoriasis</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNo9kMlOwzAURSMEElXpP0SwTvGYxMuqYpIqAQLWlu08K26bATutgFU3fAF_2C8hbSmrN-je93RPFF1iNMaYptcwL9tS-SohiKAEVNmaprZjSrOTaEAQyxIhUnb63_P0PBqF4DTilOaCUTGI1vzp5Tnp_dvN96RWy8_gQtzYuCshBmvBdG4NNYT9MoBZLVy9qpSOVV3E7gMW7ms_unpv6TyoroK628mrpgCvOthufgKswUPchsY71b-4iM6sWgYY_dVh9HZ78zq9T2aPdw_TySzRmKRZYgpNsCVGcCNEoSlwgxXHCDJkOdPAmFCUaZtZhJQ2fSxS5CrNjcKsMNbSYXR1uNv65n0FoZPzZuX7nEESmhNB0xRnvYofVLqay9a7SvlPiZHcUZZHynJHWR4py54y_QUxdXm5</recordid><startdate>202003</startdate><enddate>202003</enddate><creator>Sanchez Matamoros Piazza, MDV</creator><creator>Varas Perez, A</creator><creator>Puivecino Moreno, C</creator><creator>Cuadros Martinez, C</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>202003</creationdate><title>5PSQ-020 Analysis of the effectiveness of secukinumab and ixekizumab in the treatment of moderate–severe psoriasis</title><author>Sanchez Matamoros Piazza, MDV ; Varas Perez, A ; Puivecino Moreno, C ; Cuadros Martinez, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1267-cdb21f2c95c99db3e5c1a510e70f54be449a34bf7f00abc5332d8a68ca14dcff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Monoclonal antibodies</topic><topic>Psoriasis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sanchez Matamoros Piazza, MDV</creatorcontrib><creatorcontrib>Varas Perez, A</creatorcontrib><creatorcontrib>Puivecino Moreno, C</creatorcontrib><creatorcontrib>Cuadros Martinez, C</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sanchez Matamoros Piazza, MDV</au><au>Varas Perez, A</au><au>Puivecino Moreno, C</au><au>Cuadros Martinez, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>5PSQ-020 Analysis of the effectiveness of secukinumab and ixekizumab in the treatment of moderate–severe psoriasis</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><date>2020-03</date><risdate>2020</risdate><volume>27</volume><issue>Suppl 1</issue><spage>A159</spage><epage>A159</epage><pages>A159-A159</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>Background and importanceThere are currently two drugs with the same mechanism of action, inhibitors of interleukin 17 (anti-IL-17), for the treatment of moderate–severe psoriasis.Aim and objectivesTo evaluate the efficacy of secukinumab and ixekizumab in terms of psoriasis area severity index (PASI) and dermatology life quality index (DLQI) in the treatment of moderate–severe psoriasisMaterial and methodsA retrospective observational study was conducted in patients treated with secukinumab and ixekizumab from February 2016 to October 2019. The variables collected were sex, diagnosis and previous biological treatment. The variation in PASI and DLQI were studied as the main efficacy variables. Data were obtained from the record of dispensation of outpatients and the electronic medical history.ResultsEighty-four patients were included, 44% were men. In 50% of cases the anti-IL-17 drug was used as the firstline biological treatment, in 27% of cases as the secondline, in 6% as the thirdline and in 7% as the fourthline or successive treatment. The baseline average PASI was 6.87 (SD=3.5) and the average DLQI was 7.07 (SD=3.73). Twenty-one patients could not be evaluated due to lack of data recorded after the start of the anti-IL-17 drug. The percentage of patients with a reduced PASI was 9.52%, 19.05% and 44.44% for PASI 75/90/100, respectively: 63.16% obtained a DLQI after the start of treatment of 0–1.Conclusion and relevanceSecukinumab and ixekizumab demonstrated effectiveness, representing a good therapeutic option for moderate to severe plaque psoriasis, including in both naive and patients refractory to other biological treatments. It is necessary to continue monitoring these patients to study the long term results.References and/or acknowledgementsNo conflict of interest.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/ejhpharm-2020-eahpconf.337</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2047-9956 |
ispartof | European journal of hospital pharmacy. Science and practice, 2020-03, Vol.27 (Suppl 1), p.A159-A159 |
issn | 2047-9956 2047-9964 |
language | eng |
recordid | cdi_proquest_journals_2382936617 |
source | Open Access: PubMed Central |
subjects | Monoclonal antibodies Psoriasis |
title | 5PSQ-020 Analysis of the effectiveness of secukinumab and ixekizumab in the treatment of moderate–severe psoriasis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T21%3A37%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=5PSQ-020%E2%80%85Analysis%20of%20the%20effectiveness%20of%20secukinumab%20and%20ixekizumab%20in%20the%20treatment%20of%20moderate%E2%80%93severe%20psoriasis&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Sanchez%20Matamoros%20Piazza,%20MDV&rft.date=2020-03&rft.volume=27&rft.issue=Suppl%201&rft.spage=A159&rft.epage=A159&rft.pages=A159-A159&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2020-eahpconf.337&rft_dat=%3Cproquest_bmj_p%3E2382936617%3C/proquest_bmj_p%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b1267-cdb21f2c95c99db3e5c1a510e70f54be449a34bf7f00abc5332d8a68ca14dcff3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2382936617&rft_id=info:pmid/&rfr_iscdi=true |